Simplify Asset Management’s Regenxbio RGNX Stock Holding History

Simplify Asset Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-38,000	Closed	-$547K	–	169
2025 Q4	$547K	Buy	+38,000	New	+$474K	0.01%	99

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Simplify Asset Management's RGNX Position: Q1 2026 in Review

Simplify Asset Management sold out of Regenxbio (RGNX) in Q1 2026, closing a stake of 38,000 shares — an estimated $547K sold.

Simplify Asset Management first reported a position in RGNX in Q4 2025 and held it in 1 quarter. The position peaked at $547K in Q4 2025. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

Simplify Asset Management reported no remaining Regenxbio position as of Q1 2026 after selling out during the quarter.
Simplify Asset Management sold 38,000 Regenxbio shares in Q1 2026, an estimated $547K.
Simplify Asset Management first reported a position in Regenxbio in Q4 2025 and held it in 1 quarter.
Simplify Asset Management's Regenxbio position peaked at $547K in Q4 2025.
178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Simplify Asset Management's 13F filing for Q1 2026, filed 27 Apr 2026.